TRANSPOSAGEN BIOPHARMACEUTICALS, INC.
|TRANSPOSAGEN BIOPHARMACEUTICALS, INC. Patent applications|
|Patent application number||Title||Published|
|20140201858||METHODS FOR SITE-SPECIFIC GENETIC MODIFICATION IN STEM CELLS USING XANTHOMONAS TAL NUCLEASES (XTN) FOR THE CREATION OF MODEL ORGANISMS - The invention relates to organisms and compositions comprising one or more stem cells or one or more embryos, wherein the one or more stem cells or one or more embryos comprise one or more of the following mutations: (i) a deletion mutation; (ii) a knockout mutation; and/or (iii) an addition of a heterologous nucleic acid sequence; wherein the one or more mutations of (i), (ii), and/or (iii) are site-specific mutations caused by a||07-17-2014|
|20140041063||Genetically Modified Rat Models for Obesity and Diabetes - This invention relates to a genetically modified or chimeric rat cell whose genome comprises chromosomal alleles of an obesity-diabetes gene (especially, the Mc4r gene or Lep gene), wherein at least one of the two alleles contains a mutation, or the progeny of this cell. The obesity or diabetes gene may affect any of the pathways of obesity and diabetes. The obesity or diabetes gene may predispose the rat to a phenotype of obese and diabetic, lean and diabetic, obese and non-diabetic, non-obese and diabetic or any of the combinations thereof. In another aspect, the invention relates to a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to obesity or diabetes.||02-06-2014|
|20130160152||Hyperactive Piggybac Transposases - The present invention provides PiggyBac transposase proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.||06-20-2013|
|20120148604||TRP INHIBITORS AND USES THEREOF - The present invention, relates to methods including compounds, derivatives, antibodies, interfering RNA, biologies, polypeptides, dominant negative effectors, and their use in the treatment of neuropathic pain by inhibition of transient receptor potential (TRP) channels. In another embodiment, this invention relates to inhibitors, antagonists, and agonists of TRPC4. TRPC4 therapeutic agents and modulators include but are not limited to small molecule inhibitors, compounds, amino acid derivatives, polypeptides, RNA interference agents, natural chemicals, ligand derivatives, and ions. TRPC4 therapeutic agents and modulators are developed for the treatment of neuropathic pain, including but not limited to pain sensations such as nociception, hyperalgesia, allodynia, and loss of sensory function.||06-14-2012|
Patent applications by TRANSPOSAGEN BIOPHARMACEUTICALS, INC.